OC-0167: Advanced left-side breast cancer: does VMAT allow doses of organs at risk to be reduced?

P.C. Yu, H.H. Nien, C.J. Wu, Y.L. Tsai
2016 Radiotherapy and Oncology  
S78 ESTRO 35 2016 _____________________________________________________________________________________________________ research purposes, but not used for clinical decision making. Doses to the PTV, lung, heart and LAD were recorded. Four patient groups were identified for comparison: those who had at least one heart parameter worse with DIBH, minimal benefit arbitrarily defined as less than 20%, moderate benefit defined as between 20%-70% and a major benefit defined as greater than 70%.
doi:10.1016/s0167-8140(16)31416-5 fatcat:czx2r6hzufcftlhtguw4qfg23i